FDA Eases Rules for Simple COVID Rapid Tests
Published Date: 6/11/2026
Rule
Summary
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
New study, labeling, and submission requirements
Manufacturers must submit a premarket notification (510(k)) for these Class II tests and meet detailed special controls in 21 CFR 866.3982, including labeling elements, intended use limited to respiratory specimens, and clinical and analytical study requirements. Clinical evidence must include a prospective multisite study with geographically diverse samples compared to an FDA-accepted molecular comparator, and performance criteria requiring the lower bound of the two-sided 95% confidence interval for positive percent agreement to be ≥80% (or ≥70% with additional mitigations).
Faster patient access to COVID tests
The FDA has put simple point-of-care COVID-19 rapid tests into Class II, which the agency says will enhance patients' access to these tests by reducing regulatory burdens. The order is effective June 11, 2026, and the classification was applicable on March 8, 2023.
Easier market path for device makers
FDA classified simple near-patient SARS-CoV-2 tests as Class II, allowing these devices to serve as predicates for future devices and enabling sponsors to use the less-burdensome 510(k) pathway instead of premarket approval. The order is effective June 11, 2026, and the classification was applicable on March 8, 2023.
Emergency testing and rapid reporting duties
If certain actions under section 564(b)(1)(A)-(D) occur or HHS declares a public health emergency under section 319(a), manufacturers must test devices with FDA‑provided characterized samples within 30 days of notification and must include results in device labeling within 60 days; those labeling entries must remain for 3 years. FDA may also request evaluation results to be submitted within 48 hours.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-15345, Food Safety Modernization Act Voluntary Qualified Importer Program User Fee Rate for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) that is authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). This fee is effective on August 1, 2026, and will remain in effect through September 30, 2027.
2026-15336, Food Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 fee rates for certain domestic and foreign facility reinspections, failures to comply with a recall order, and importer reinspections that are authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA).
2026-15346, Biosimilar User Fee Rates for Fiscal Year 2027
Starting October 1, 2026, companies making biosimilar drugs will pay updated fees to the FDA for developing and getting approval for their products. These fees cover new drug development, application reviews, and yearly program costs. This helps the FDA keep biosimilar drug reviews speedy and fair while supporting innovation.
2026-15335, Medical Device User Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA, Agency, or we) is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device User Fee Amendments of 2022 (MDUFA V), authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. This notice establishes the fee rates for FY 2027, which apply from October 1, 2026, through September 30, 2027, and provides information on how the fees for FY 2027 were determined, the payment procedures you should follow, and how you may qualify for reduced small business fees.
Previous / Next Documents
Previous: 2026-11732, Air Plan Approval; New York; New York Metropolitan Area Second Ten-Year Limited Maintenance Plan for the 2006 24-Hour PM2.5 Standard
The EPA is giving a thumbs-up to New York’s plan to keep the air clean in 10 counties around New York City for the next ten years, focusing on tiny pollution particles called PM2.5. This plan, effective July 13, 2026, helps protect people’s health without adding new costs or rules. If you live or work in the New York metro area, breathe easy knowing the air quality plan is locked in and ready to roll!
Next: 2026-11740, Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.